SCHEMBL6501165

SCHEMBL6501165

Clc1cccc(Cl)c1CSc1nnc(-c2ccccc2)s1

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.80
ATM Q13315 1/20 0.80
PIEZO1 Q92508 1/20 0.61
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
LMNA P02545 2/20 0.47
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
GSK3B P49841 1/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 2/20 0.44
HTT P42858 1/20 0.44
ABL1 P00519 1/20 0.43
SRC P12931 1/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
TERT O14746 1/20 0.43
ELANE P08246 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31520560 0.87 ALDH1A1 (0.74) ALDH1A1ATMPIEZO1MEN1KMT2A
SCHEMBL6492979 0.81 MEN1 (0.59) ALDH1A1ATMMEN1KMT2ALMNA
SCHEMBL31520558 0.79 ALDH1A1 (0.62) ALDH1A1ATMPIEZO1MEN1KMT2A
SCHEMBL19376839 0.77 LMNA (0.71) ALDH1A1ATMPIEZO1LMNAGAA
SCHEMBL28419773 0.77 MEN1 (0.59) ALDH1A1ATMMEN1KMT2ALMNA
SCHEMBL6490578 0.76 PIEZO1 (1.00) ALDH1A1ATMPIEZO1MEN1KMT2A
SCHEMBL31520563 0.75 PIEZO1 (0.69) ALDH1A1ATMPIEZO1MEN1KMT2A
SCHEMBL11117696 0.74 PKM (0.47) ALDH1A1ATMMEN1KMT2ALMNA
SCHEMBL28427660 0.72 ALDH1A1 (0.45) ALDH1A1ATMMEN1KMT2ALMNA
SCHEMBL28425477 0.72 MEN1 (0.50) ALDH1A1ATMPIEZO1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894054-B2 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. (US) 2005-05-17 US claimed
EP-1357913-A1 HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 TELIK, INC. (US) 2003-11-05 EP claimed
US-20030073726-A1 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. 2003-04-17 US claimed
WO-2002064135-A1 HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 TELIK, INC. (US) 2002-08-22 WO claimed
US-6894054-B2 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. (US) 2005-05-17 US disclosed
EP-1357913-A1 HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 TELIK, INC. (US) 2003-11-05 EP disclosed
US-20030073726-A1 Heterocyclic inhibitors of glycine transporter 2 TELIK, INC. 2003-04-17 US disclosed
WO-2002064135-A1 HETEROCYCLIC INHIBITORS OF GLYCINE TRANSPORTER 2 TELIK, INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073726-A1 Heterocyclic inhibitors of glycine transporter 2 SLC1A2, SLC1A1, SLC1A3 ALDH1A1 3710/4885ATM 4470/4885PIEZO1 2298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.